Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of...
New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health
Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of...
NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections
The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies,...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...
Beijing Balance Medical Technology’s ePTFE Implant Accepted for NMPA Review
Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that the National Medical Products...
Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
China’s Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from...
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO)...
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced...
Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced...
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing...
Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies...
Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
Shanghai-based nucleic acid drug developer Rona Therapeutics has announced the presentation of positive Phase I...
Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results...
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to...
AstraZeneca’s Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that the Committee for...
Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that it has received full approval from the...